| Literature DB >> 25250320 |
Jana Lillo1, Kristiine Pai1, Arta Balode2, Mariia Makarova3, Kristi Huik1, Siiri Kõljalg1, Marina Ivanova4, Lidia Kaftyreva3, Jolanta Miciuleviciene5, Paul Naaber6, Kristel Parv1, Anastasia Pavelkovich4, Tiiu Rööp1, Karolin Toompere1, Ludmila Suzhaeva3, Epp Sepp1.
Abstract
The aim of this study was to compare the prevalence of different virulence factor (VF) genes in extended-spectrum beta-lactamase (ESBL) producing Escherichia coli strains isolated from the Baltic Sea region. A total of 432 strains of phenotypically ESBL positive E. coli were collected from 20 institutions located in Estonia, Latvia, Lithuania, and the region of St. Petersburg in Russia from January to May 2012 and analyzed for phylogenetic group and prevalence of 23 VF genes. The strains were collected from clinical material (urine, blood, wound, and respiratory tract). Bacterial isolates were compared according to phylogenetic group, clinical material, and geographical origin. Most of the VF genes were concentrated within phylogenetic group B2 and/or D. When comparing strains isolated from different countries, it was found that strains originating from Estonia and Latvia belonged mainly to group B2 and strains from Lithuania and Russia mainly to groups B2 and D. The P-fimbrial adhesin gene papEF was more prevalent in Russian strains, colicin gene cvaC in Lithuanian strains, and capsular gene kpsMTII in Latvian strains; serum resistant gene traT was less prevalent in Estonian strains. The regional differences of VF genes remained statistically significant after taking into account the phylogenetic distribution in the countries.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25250320 PMCID: PMC4164513 DOI: 10.1155/2014/427254
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Number of ESBL producing E. coli strains isolated from different countries and materials.
| Origin of strains ( | Estonia | Latvia | Lithuania | Russia |
|---|---|---|---|---|
| Urine ( | 110 (74%) | 52 (46%) | 19 (54%) | 85 (67%) |
| Blood ( | 7 (5%) | 8 (7%) | 7 (20%) | 5 (4%) |
| Wound ( | 23 (15%) | 37 (33%) | 7 (20%) | 25 (20%) |
| Respiratory tract ( | 9 (6%) | 15 (13%) | 2 (6%) | 12 (9%) |
The prevalence of 23 VF genes among 423 extraintestinal ESBL producing E. coli strains, isolated from the Baltic Sea region.
| VF | Gene | Prevalence |
|---|---|---|
| Adhesins |
| 0 (0) |
|
| 399 (94) | |
|
| 5 (1) | |
|
| 2 (0.5) | |
|
| 65 (15) | |
|
| 101 (24) | |
|
| 67 (16) | |
|
| 0 (0) | |
|
| 71 (17) | |
|
| 8 (2) | |
|
| 45 (11) | |
|
| ||
| Toxins |
| 68 (16) |
|
| 49 (12) | |
|
| 2 (0.5) | |
|
| ||
| Capsule |
| 251 (59) |
|
| 22 (5) | |
|
| 5 (1) | |
|
| 204 (48) | |
|
| ||
| Siderophores |
| 352 (83) |
|
| 341 (81) | |
|
| ||
| Invasin |
| 37 (9) |
|
| ||
| Pathogenicity island |
| 215 (51) |
|
| ||
| Serum resistance |
| 364 (86) |
VF-s exhibiting significant prevalence differences according to phylogenetic distribution among 423 extraintestinal ESBL producing E. coli strains, isolated from Baltic Sea region.
| VF | Gene | Number of isolates (% of total) |
| |||
|---|---|---|---|---|---|---|
| Aa
| B1b
| B2c
| Dd
| |||
| Adhesins |
| 3 (12) | 0 (0) | 44 (15) | 19 (24) | 0.02bd |
|
| 4 (15) | 0 (0) | 73 (24) | 24 (30) | <0.02bc,bd | |
|
| 1 (4) | 0 (0) | 44 (15) | 22 (27) | <0.02ad,bd,cd | |
|
| 1 (4) | 1 (6) | 50 (17) | 19 (24) | 0.02ad | |
|
| 19 (73) | 16 (94) | 288 (96) | 76 (95) | <0.001ac,ad | |
|
| ||||||
| Toxins |
| 0 (0) | 0 (0) | 53 (18) | 15 (19) | <0.02ac,ad |
|
| 7 (27) | 5 (29) | 23 (8) | 14 (17) | 0.005ac; | |
|
| ||||||
| Capsule |
| 2 (8) | 3 (18) | 174 (58) | 25 (31) | <0.001ac,bc,cd; 0.02ad |
|
| ||||||
| Siderophore |
| 15 (58) | 11 (65) | 263 (88) | 63 (79) | <0.001ac; |
|
| 17 (65) | 13 (76) | 242 (81) | 69 (86) | 0.04ad | |
|
| ||||||
| Pathogenicity island |
| 3 (11) | 5 (29) | 186 (62) | 21 (26) | <0.001ac,cd
|
|
| ||||||
| Serum resistance |
| 18 (69) | 14 (82) | 262 (87) | 70 (87) | <0.04ac,ad |
a,b,c,dIndicate strains isolated from different phylogenetic groups.
Phylogenetic distribution of 423 extraintestinal ESBL producing E. coli strains isolated from different countries.
| Phylogenetic group | Number of isolates (% of total) |
| |||
|---|---|---|---|---|---|
| Estoniaa ( | Latviab ( | Lithuaniac ( | Russiad ( | ||
| A | 11 (7) | 3 (3) | 3 (9) | 9 (7) | — |
|
| |||||
| B1 | 3 (2) | 2 (2) | 1 (3) | 11 (9) | <0.02ad,bd |
|
| |||||
| B2 | 121 (81) | 100 (89) | 22 (63) | 57 (45) | 0.02ac; |
|
| |||||
| D | 14 (9) | 7 (6) | 9 (26) | 50 (39) | 0.02ac; |
a,b,c,dIndicate strains isolated from different countries.
VF-s exhibiting significant prevalence differences according to geographical origin among 423 ESBL producing E. coli strains.
| VF | Gene | Number of isolates (% of total) |
| |||
|---|---|---|---|---|---|---|
| Estoniaa
| Latviab
| Lithuaniac
| Russiad
| |||
| Adhesins |
| 14 (9) | 8 (7) | 5 (14) | 38 (30) | ≤0.001ad,bd |
|
| 13 (9) | 10 (9) | 3 (9) | 41 (32) | ≤0.001ad,cd; | |
|
| 20 (13) | 29 (26) | 6 (17) | 46 (36) | ≤0.05ab,cd; | |
|
| 3 (2) | 24 (21) | 4 (11) | 40 (31) | ≤0.02ac,cd; | |
|
| 28 (19) | 9 (8) | 5 (14) | 3 (2) | ≤0.02ab,cd; | |
|
| 2 (1) | 1 (1) | 2 (6) | 0 (0) | 0.05cd | |
|
| ||||||
| Toxins |
| 24 (16) | 12 (11) | 4 (11) | 28 (22) | 0.02bd |
|
| 18 (12) | 13 (12) | 10 (29) | 8 (6) | ≤0.03ac,bc; | |
|
| ||||||
| Capsule |
| 78 (52) | 77 (69) | 9 (26) | 40 (31) | ≤0.008ab,ac,ad; ≤0.001bc,bd |
|
| 81 (54) | 80 (71) | 27 (77) | 63 (50) | 0.01ac; | |
|
| 0 (0) | 0 (0) | 1 (3) | 4 (3) | 0.04ad | |
|
| ||||||
| Siderophores |
| 125 (84) | 90 (80) | 25 (71) | 112 (88) | 0.03cd |
|
| 106 (71) | 101 (90) | 28 (74) | 108 (85) | 0.02bc; | |
|
| ||||||
| Invasin |
| 27 (18) | 3 (3) | 4 (11) | 3 (2) | 0.04cd; |
|
| ||||||
| Serum resistance |
| 110 (74) | 110 (98) | 33 (94) | 111 (87) | ≤0.007ac,ad,bd
|
a,b,c,dIndicate strains isolated from different countries.
Estimated odds ratios (OR) and 95% confidence intervals (CI) for carrying of all VF genes and genes belonging to specific VF groups.
| VF genes | OR (95% Cl) | |||||||
|---|---|---|---|---|---|---|---|---|
| Countries | Phylogenetic groups | |||||||
| Estonia | Latvia | Lithuania | Russia | A | B1 | B2 | D | |
| All VF genes | 1 |
| 1.1 | 1.1 | 1 |
|
|
|
|
| ||||||||
| Adhesins | 1 | 1.0 | 1.1 |
| 1 |
|
|
|
|
| ||||||||
| Capsule synthesis genes | 1.3 |
|
| 1 | 1 | 1.2 |
| 1.4 |
|
| ||||||||
| Toxins | 1.3 | 1 | 1.8 | 1.1 | 1.0 | 1.2 | 1 | 1.5 |
|
| ||||||||
| Siderophores | 1.2 | 1.8 | 1 |
| 1 | 1.2 |
|
|
*Statistically significant OR.